ANDA 88212, held by Chartwell Rx. Cyproheptadine Hydrochloride.
As of Nov 16, 2026, ANDA 88212 (Cyproheptadine Hydrochloride), held by Chartwell Rx, was first approved by FDA on May 26, 1983, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Perennial and seasonal allergic rhinitis, Vasomotor rhinitis, Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Cold urticaria. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 26, 1983 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cyproheptadine Hydrochloride4MG · tablet;oral | Cyproheptadine Hydrochloride | Rx |
| Oct 6, 2000 | Supplement 14Manufacturing | Approved | None posted |
| May 12, 1997 | Supplement 12Labeling | Approved | None posted |
| Mar 4, 1991 | Supplement 9Labeling | Approved | None posted |
| Nov 20, 1989 | Supplement 8Labeling | Approved | None posted |
| Oct 10, 1989 | Supplement 6Manufacturing | Approved | None posted |
| Mar 10, 1988 | Supplement 4Manufacturing | Approved | None posted |
| Nov 16, 1983 | Supplement 1Manufacturing | Approved | None posted |
| May 26, 1983 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters